Enhertu for HER2-Low and -Ultralow Metastatic Breast Cancer

At the 2024 San Antonio Breast Cancer Symposium, Dr. Aditya Bardia, director of the Breast Oncology Program and Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center, presented results from the DESTINY-Breast06 study, showing that Enhertu (chemical name: fam-trastuzumab deruxtecan-nxki), also called T-DXd, was better than chemotherapy for metastatic, hormone receptor-positive, HER2-low or -ultralow breast cancer that grew after one or more hormonal therapy medicines. Listen to the episode to hear Dr. Bardia explain: results of the study what HER2-low and -ultralow breast cancer is whether people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer should have additional HER2 testing

There are no comments yet.

Please log in to write the first comment.